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Abstract
Glioblastoma stem cells (GSC) co-exhibiting a tumor-initiating capacity and a radio-chemore-
sistant phenotype, are a compelling cell model for explaining tumor recurrence. We have pre-
viously characterized patient-derived, treatment-resistant GSC clones (TRGC) that survived
radiochemotherapy. Compared to glucose-dependent, treatment-sensitive GSC clones
(TSGC), TRGC exhibited reduced glucose dependence that favor the fatty acid oxidation
pathway as their energy source. Using comparative genome-wide transcriptome analysis, a
series of defense signatures associated with TRGC survival were identified and verified by
siRNA-based gene knockdown experiments that led to loss of cell integrity. In this study, we
investigate the prognostic value of defense signatures in glioblastoma (GBM) patients using
gene expression analysis with Probeset Analyzer (131 GBM) and The Cancer Genome Atlas
(TCGA) data, and protein expression with a tissue microarray (50 GBM), yielding the first
TRGC-derived prognostic biomarkers for GBM patients. Ribosomal protein S11 (RPS11),
RPS20, individually and together, consistently predicted poor survival of newly diagnosed pri-
mary GBM tumors when overexpressed at the RNA or protein level [RPS11: Hazard Ratio
(HR) = 11.5, p<0.001; RPS20: HR = 4.5, p = 0.03; RPS11+RPS20: HR = 17.99, p = 0.001].
The prognostic significance of RPS11 and RPS20 was further supported by whole tissue
section RPS11 immunostaining (27 GBM; HR = 4.05, p = 0.01) and TCGA gene expression
data (578 primary GBM; RPS11: HR = 1.19, p = 0.06; RPS20: HR = 1.25, p = 0.02; RPS11
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+RPS20: HR = 1.43, p = 0.01). Moreover, tumors that exhibited unmethylated O-6-methyl-
guanine-DNAmethyltransferase (MGMT) or wild-type isocitrate dehydrogenase 1 (IDH1)
were associated with higher RPS11 expression levels [corr (IDH1, RPS11) = 0.64, p = 0.03);
[corr (MGMT, RPS11) = 0.52, p = 0.04]. These data indicate that increased expression of
RPS11 and RPS20 predicts shorter patient survival. The study also suggests that TRGC are
clinically relevant cells that represent resistant tumorigenic clones from patient tumors and
that their properties, at least in part, are reflected in poor-prognosis GBM. The screening of
TRGC signatures may represent a novel alternative strategy for identifying new prognostic
biomarkers.
Introduction
Glioblastoma (GBM) WHO grade IV is the most common and aggressive brain tumor in
adults, and currently has no cure. Temozolomide (TMZ), administered concurrently with and
without radiation therapy (RT), is the standard first-line treatment in GBM [1–4]. Methylation
of the O-6-methylguanine-DNAmethyltransferase (MGMT) promoter has emerged as an
important prognostic and predictive factor for TMZ treatment of newly diagnosed GBM [5].
Likewise, mutations in isocitrate dehydrogenase (IDH) predict a good prognosis, and are more
frequently seen in secondary GBM [6]. However, despite the best efforts of gross total resection
and post-operative radiochemotherapy, most patients still develop tumor recurrence. The
overall 5-year survival rate is lower than 10%, and the 10-year mortality rate is nearly 100% [3].
Bevacizumab, an anti-angiogenic drug, was designed to block vascular endothelial growth fac-
tor (VEGFA), and is FDA-approved as the second-line therapy for treating recurrent GBM.
However, while improving progression-free survival, the addition of bevacizumab to RT-TMZ
did not improve survival in patients with glioblastoma [7, 8, 9]. Moreover, the rate of adverse
events was actually higher with bevacizumab than with placebo [8, 9]. Thus, identification of
novel treatment targets associated with patient prognosis for GBM remains a highly important
goal.
Glioblastoma stem cells (GSC) or stem-like glioblastoma-initiating cells (GIC) are a signifi-
cant preclinical model for explaining and testing the mechanisms underlying post-treatment
tumor recurrence, because these patient tumor-derived cells exhibit a tumorigenic capacity
[10–15], a highly migratory nature [15–16], and a radio-chemoresistant phenotype [17–19].
We previously reported that neurosphere formation is an independent predictor of glioma
tumor progression independent of Ki67 proliferation index and suggested that the ability to
propagate GSC in vitro is associated with clinical outcome [20]. These findings lend support to
the view that upregulation of GSC-associated properties and activity in tumors may be associ-
ated with poor prognosis in GBM patients. Although CD133 is not a defining marker of GSC,
the CD133 antigen has been identified as a putative stem cell marker in normal and malignant
brain tissues and was the first surface marker utilized for the enrichment of GSC [10, 11, 13,
15]. The prognostic value of CD133 in GBM has been evaluated by several independent groups
[21–23]. The proportion of CD133+ cells in tumor tissues is an independent risk factor for
tumor regrowth and for time to malignant progression [21]. Moreover, high expression levels
of CD133 is associated with a shorter time to recurrence at locations distant from the original
site [22] and with higher grades of glioma as well as a worse prognosis [23]. More recently,
LGR5 (leucine-rich repeat-containing G protein-coupled receptor 5), a novel stem cell marker
of the intestinal epithelium and the hair follicle, was reported to be a poor prognostic factor in
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GBM and to be required for survival of glioblastoma stem-like cells [24]. Interestingly, we pre-
viously found that upregulated LGR5 is a shared marker of CD133+ GSC when compared to
CD133-GSC [15] and upregulation of LGR5 was also detected in GSC that survived high-dose
TMZ treatment when compared to untreated parental GSC (unpublished data). These findings
suggested that upregulated genes in GSC with a stress-resistant phenotype might be a good
resource for identifying novel biomarkers that predict the outcome of GBM patients.
Previously, to explore the potential mechanisms underlying treatment resistance of GBM,
we isolated and characterized tumorigenic GSC clones that survived radiochemotherapy [25].
We found that, even under glucose-containing culture condition supplemented with insulin,
these quiescent treatment-resistant GSC clones (TRGC) expressed a glucose restriction (GR)-
like phenotype, and used lipid catabolism pathways in mitochondria as their primary energy
source, whereas their autologous treatment–sensitive GSC clones (TSGC) were highly depen-
dent on glycolysis for ATP production [25]. Functionally, TRGC upregulate CD133/SOX2,
and exhibit increased autophagic activity and AMP-activated protein kinase (AMPK)-SIRT1
signaling. Additionally, upregulated genes are associated with global DNA repair activity,
pointing to a metabolic stress-induced protective response for stabilizing cellular, molecular
and genomic integrity [26–33]. Concurrently, the molecular defense signatures of TRGC iden-
tified via comparative expression microarray analysis resemble anti-aging and anti-stress
effects of a GR-like phenotype [34, 35]. The siRNA-based on-target gene knockdown experi-
ments further confirmed the role of selected defense signatures in stress-resistance of TRGC
[25] and suggested that the molecular response programs essential for self-defense in TRGC
are likely to at least partially contribute to the development of treatment resistance and tumor
recurrence.
In this study, we extend our prior work and test the hypothesis that defense signatures upre-
gulated in TRGC are able to serve as prognostic factors for GBM patients. We screened a subset
of TRGC signatures in GBM surgical samples and The Cancer Genome Atlas (TCGA) dataset,
and have identified novel TRGC-derived biomarkers predictive of poor prognosis in patients
with newly diagnosed GBM.
Materials and Methods
Probe Set Analyzer correlation of gene expression with GBM patient
survival curves
To assess the correlation of transcriptional levels of defense signatures in patient tumors with
patient survival, Probe Set Analyzer, a free publicly available, web-based interactive tool for
real time correlation of gene expression values and patient survival was employed. The tool
was created and developed through a collaboration between UCLA Neuro-Oncology, UCLA
Human Genetics and SiliconMED (http://probesetanalyzer.com). The arrays and survival data
were derived from consented patients treated by the UCLA Neuro-Oncology program. The
expression microarray data consists of 22,000 probe sets analyzed on 131 GBM, including 67
newly diagnosed and 64 recurrent GBM. Recurrent GBM are cases where tumors were previ-
ously diagnosed as GBM, whether primary or secondary, and recurred. In neurooncology ter-
minology, primary GBM are defined as tumors that present at first diagnosis as GBM, without
apparent evolution from a low grade glioma [36]. Secondary GBM, in contrast, are designated
as such if the patient first presented with a lower grade glioma (Grade II or Grade III) and sub-
sequently transformed into a GBMWHO Grade IV. The Probe Set Analyzer dataset does not
distinguish primary from secondary GBM. The Probe Set Analyzer generated Kaplan-Meier
curves for different gene expression levels (Low, Mid, High) and also determined whether the
curves were statistically significant providing a Log-rank test p-value.
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Immunohistochemical analysis of a glioblastoma tissue microarray
(TMA)
A GBM tissue microarray was constructed consisting of three representative 1-mm cores from
formalin-fixed, paraffin-embedded (FFPE) tissue blocks from each one of 50 GBM patients.
All GBM tumor specimens were obtained from patients who underwent surgery at Ronald Rea-
gan UCLAMedical Center. All samples collected were under patients’ written consent, and
were approved by the UCLA Institutional Review Board. Twenty-eight were newly diagnosed
GBM and 22 were recurrent GBM. 21 of the newly diagnosed GBM were primary GBM and 7
were secondary GBM. Eighteen recurrent GBM were primary GBM and 4 were secondary
GBM. Immunohistochemical analysis was performed on 5-μm FFPE sections of TMAs. Anti-
gen retrieval was performed by immersing TMA slides into a 1X Dako Target Retrieval buffer
for 40 min in a pressure cooker. Endogenous peroxidase activity was quenched with 3% hydro-
gen peroxide in PBS. TMA sections were incubated with diluted primary antibodies ribosomal
protein S11 (RPS11) at 1:25, ribosomal protein S20 (RPS20) at 1:100, Vascular endothelial
growth factor A (VEGFA) at 1:50 (Prestige Antibodies1, Sigma, St. Louis, MO) for 16 h at
4°C, followed by incubation with MACH-3 (Rabbit) or MACH-4 (Mouse) secondary antibod-
ies (Biocare Medical, Concord, CA) for 30 minutes at room temperature. Subsequent immuno-
detection was completed using Vector NovaRed (Vector Laboratories, Burlingame, CA).
Immunohistochemical staining of whole tissue sections of newly
diagnosed primary glioblastoma
Five micrometer thick-whole tissue sections were cut from paraffin blocks of 27 newly diag-
nosed GBM. These cases had available MGMTmethylation-specific polymerase chain reaction
(PCR) and IDH1 immunohistochemistry or PCR results. Thirteen cases of these whole tissue
sections were of tumors previously represented on the TMA and had adequate tissue for fur-
ther study. Many cases had limited tissue after three cores were obtained for the TMA and
were not suitable for whole tissue section immunostaining. Another 14 cases were additional
newly diagnosed GBM not on the TMA. Immunostaining was performed as described above.
Scoring and interpretation of immunohistochemistry
Tissue microarray sections were separately stained with each selected antibody. Individual anti-
body stains were screened by a pathologist (W.Y.) for variability of staining intensity between
cases on the premise that a high degree of variability between GBM cases would permit more
robust correlation with survival than stains that showed scant differences between cases.
Immunohistochemistry for these immunostains were scored semi-quantitatively. Intensity of
staining was scored on a scale of 0–3 (0 = no staining; 1 = weak; 2 = moderate; 3 = strong). The
percentage of tumor cells expressing each level of intensity was also scored. An H score
(range = 0–300) for each stained tumor was generated by multiplying the percentages by their
intensity score and adding up the products of multiplication [37, 38].
Statistical analysis for immunohistochemistry using Cox Proportional
Hazard Analysis (Pairwise analyses- Optimal binning)
The H-scores for RPS11, RPS20, and VEGFA were assessed for association with survival. Sur-
vival was defined from the first day of surgery to the last day of follow up or death. We investi-
gated if an H-score specific for each of the 3 proteins could be found to best discriminate
between patients’ prognostic outcomes. For each protein, we considered several possible aver-
age expression values to define high versus low expression groups. For each grouping scenario,
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we fitted a Cox Proportional Hazards model and computed the model score (Fig 1). The
model with the highest score should indicate the protein-specific expression cut-off that best
discriminates between patients with poor and best survival. For VEGFA, the 80th percentile
was used as modeling did not identify optimal binning. The determined optimal cutoffs were
1.80 (VEGFA), 1.33 (RPS11), and 1.83 (RPS20) respectively. Association of protein expression
with all GBM, primary GBM, secondary GBM, newly diagnosed primary GBM and recurrent
GBM with survival were then analyzed with Cox Proportional Hazards (CPH) Analysis. In our
CPH analysis we consider both binned (high vs. low) protein expression and continuous
expression scores as potential predictors of survival. Differences in the death hazard were esti-
mated as HR in high vs. low expression groups. Our conclusions did not change, qualitatively,
when we considered continuous expression scores. The proportional hazard assumption was
evaluated inspecting Kaplan Meyer estimates of survival functions in the high vs. low expres-
sion groups. The CPH model was found adequate to describe differential survival. Mean pro-
tein expression of RPS11 (whole tissue sections of newly diagnosed GBM, n = 27) in MGMT
methylated GBM patients was compared against MGMT unmethylated patients using a simple
T-test. Similarly, mean expression of RPS11 in IDH1 mutant GBM patients was compared
against IDH1 wild type patients using a simple T-test.
Fig 1. Modeling of protein expression (H-score) cutoffs for low vs. high protein expression. Each curve
reports the score of a Cox Proportional Hazards model associated with different cut-off values of the related
protein expression to bin scores into Low versus High expression. Protein expression is measured as the H
score rescaled to (0–3). Optimal cut-offs are identified as the mode in the cut-off vs. score curve. For VEGFA,
this was not identifiable and an 80th percentile H-score was used as a cut-off.
doi:10.1371/journal.pone.0141334.g001
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Gene expression levels correlated with survival from The Cancer
Genome Atlas data
The TCGA (https://tcga-data.nci.nih.gov/tcga/) data repository was used to further validate
our findings in 578 newly diagnosed primary GBM patients. In the TCGA database, protein
expression in GBM was assessed with a reverse phase protein array (RPPA) platform and
mRNA gene expression measurements were obtained using Agilent Expression 244K microar-
rays. The GBM proteome data in the TCGA database was limited to 171 proteins and none of
the proteins of interest (RPS11, RPS20, and VEGFA) was included among them. We therefore
focused on analysis of TCGA gene expression data. The response of interest was survival after
diagnosis. We considered average normalized gene expression as a continuous predictor of sur-
vival, where the baseline hazard refers to subjects with average expression. The HR is to be
interpreted as the expected change in the hazard of death as expression increases by 1 standard
deviation. A binned analysis was also performed, where we compared subjects with gene
expression above average vs. subjects with gene expression below average.
Results
Probe Set Analyzer analysis shows that elevated transcription levels of
TRGC-associated genes in GBM tissues have a negative correlation
with patient survival
We have identified defense signatures of TRGC via comparative analysis of expression profiles
of TSGC and TRGC [25]. Since both populations are stem-like, tumor-initiating cells and may
only differ in their degree of differentiation, we anticipate that the defense signatures of TRGC
will be mainly associated with stress-resistant phenotype. We therefore hypothesized that
defense signatures of TRGC would be an excellent resource for identifying prognostic markers
in GBM patients. To test this hypothesis, we firstly employed Probe Set Analyzer to screen 53
defense signatures of TRGC. We found all 53 TRGC signatures could be detected in patient
tumors as indicated by Probe Set Analyzer. The association of transcriptional levels of TRGC
signatures with patients’ survival was identified either in newly diagnosed tumors, recurrent
tumors, or both (S1 Table). We found 9 markers to be significantly associated with poor prog-
nosis when expression levels were upregulated only in newly diagnosed tumors, while 12 mark-
ers were associated with shorter survival when upregulated only in recurrent tumors. We also
identified 7 markers that had prognostic value in both newly diagnosed and recurrent tumors.
Even though the MGMT promoter status, rather than the MGMT expression, is important as a
marker to predict therapy resistance, we found several TRGC markers to be better predictors
of patient survival than MGMT gene expression as indicated by the Probe Set Analyzer gene
expression data (Fig 2, S1 Fig). This data raises the possibility that subpopulations or popula-
tions of tumor cells in a GBM either convergently use or may have inherited stress resistance
pathways from TRGC contributing to the development of treatment resistance.
Elevated ribosomal protein levels in newly diagnosed GBM and primary
GBM predict poor prognosis
Based on gene function annotations, siRNA knockdown studies [25], and Probe Set Analyzer
data (Fig 2, S1 Table, S1 Fig), immunostaining of 10 selected markers was performed on sec-
tions of the GBM tissue microarray. Six markers (FMNL2, PRKCI, FOLR1, OSBPL8,
PPP1R3C, and MFAP4) (Full names of these genes are shown in S1 Table) showed relatively
uniform and strong immunohistochemical staining across cases and were not further evaluated
(data not shown). One marker (IL6ST) showed consistently weak staining across tumors and
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also was not further studied (data not shown). Three markers, RPS11, RPS20, and VEGFA,
showed a range of staining among samples and were subjected to detailed scoring. H-scores
were tabulated and subjected to statistical analysis. When all GBM were analyzed (Table 1),
high RPS11 expression was associated with a 4.3-fold increased likelihood of death, whether a
CPH binned (Table 1) or continuous score methodology (data not shown) was used. High
RPS20 expression showed a 2-fold increased likelihood of death only when using the continu-
ous score methodology (data not shown) and approached significance with a binned method-
ology. The whole GBM dataset was further subdivided into newly diagnosed or recurrent GBM
(Table 1, Fig 3). Upregulation of VEGFA and RPS11 was found to increase the hazard of death
3.5-fold and 9-fold in newly diagnosed tumors only respectively. In age-adjusted analyses,
results remain substantially unchanged (Table 1). In evaluating primary GBMs, upregulation
of RPS11 was found to increase the hazard of death 4-fold and upregulation of RPS20 was
found to increase the death hazard by 2.6-fold (Table 2). For primary GBM patients, upregula-
tion of VEGFA did not change the hazard of death significantly (Table 2). Moreover, increased
VEGFA and RPS11 expression, but not RPS20, in secondary GBM was associated with poor
prognosis (S2 Table). The primary GBM dataset was subdivided into newly diagnosed and
recurrent cohorts and analyzed with CPH analysis (Table 2). VEGFA expression was not asso-
ciated with survival in either recurrent or newly diagnosed tumors. Upregulation of RPS11 and
RPS20 was found to increase the hazard of death 11-fold and 4.5-fold, respectively, in newly
diagnosed primary GBM. In newly diagnosed primary GBM, the HR for patients with overex-
pressed proteins RPS11 or RPS20 was 1.98 (95% C.I. 0.52–7.48, p = 0.32), when compared to
patients with low RPS11 or RPS20. The HR for patients with simultaneous overexpression of
both proteins RPS11 and RPS20 was 17.99 (95% C.I. 3.01–107.55, p = 0.001) when compared
to patients with low RPS11 and RPS20 (Table 2). In age-adjusted analyses, results remain sub-
stantially unchanged (Table 2). Representative immunohistochemical staining of RPS11 and
RPS20 in clinical GBM subgroups is presented in (Fig 4). When overexpressed, RPS11 and
RPS20 were generally diffusely upregulated in the tumor cell population. However, we found
that RPS11 was the only one of the 3 biomarkers where an upregulated gene expression profile
(determined by Probe Set Analyzer) was completely concordant with increased protein expres-
sion in terms of increasing the hazard of death for newly diagnosed GBM (Table 3). Given the
consistent protein and gene expression data in RPS11, we extended evaluation of RPS11 to
whole tissue sections of newly diagnosed GBM. In whole tissue sections, we observed a 4-fold
Fig 2. Representative outputs of Probe Set Analyzer for selected molecular signatures of TRGC. A real-time correlation of patient survival and gene
expression levels of selected signatures of TRGC was performed using Probe Set Analyzer (http://probesetanalyzer.com/index.aspx). “Newly Diagnosed",
“Recurrent" or “combined all tumors” were analyzed. The y-axis represents normalized gene expression intensity, and the x-axis represents patient groups.
The sliding bars position patients into high, mid and low gene expression level groups. A Kaplan-Meier curve with corresponding p-values is generated based
on each change to these patient groups. An integrated statistical engine calculated p-values based on Kaplan-Meier curves.
doi:10.1371/journal.pone.0141334.g002
Table 1. Tissuemicroarray protein expression- Cox proportional hazard analysis (primary and secondary GBMs included).
Biomarker All GBMs Newly Diagnosed Recurrent HR (95%CI) [p value]
HR (95%CI) [p value] HR (95%CI) [p value]
RPS11 (Expression > 1.3) 4.34 (1.82–10.34) [<0.01] 9.29 (2.61–33.14) [<0.01] 2.61 (0.92–7.38) [0.13]
RPS20 (Expression > 1.8) 1.98 (0.97–4.02) [0.06] 1.45 (0.42–5.06) [0.56] 2.36 (1.06–5.23) [0.07]
VEGFA (Expression > 1.8) 1.97 (0.98–3.96) [0.06] 3.46 (1.13–10.61) [0.03] 1.12 (0.39–3.21) [0.86]
Age-adjusted estimates
RPS11 (Expression > 1.3) 3.92 (1.88–8.17) [<0.01] 5.61 (1.92–16.41) [<0.01] 2.37 (0.82–6.82) [0.18]
RPS20 (Expression > 1.8) 1.93 (1.06–3.53) [0.07] 2.73 (0.93–8.06) [0.13] 1.15 (0.47–2.83) [0.80]
VEGFA (Expression > 1.8) 1.30 (0.63–2.67) [0.55] 1.69 (0.63–4.49) [0.38] 0.78 (0.26–2.28) [0.70]
doi:10.1371/journal.pone.0141334.t001
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increase in the hazard of death, when comparing patients with high expression levels of RPS11
(expression> 1.33) to patients with low RPS11 expression levels (HR = 4.05, 95% C.I. = 1.39–
11.78, p = 0.01). Similar results were obtained considering raw protein expression scores as pre-
dictors of survival.
Elevated RPS11 protein expression is associated with unmethylated
MGMT status or wild-type IDH1 status
MGMT unmethylated status and wild-type IDH1 status are individually associated with poor
prognosis [1, 39], and the IDH1 mutation is positively associated with an MGMTmethylated
status [40]. Using the 27 cases with whole tissue sections, we also evaluated the association of
RPS11 protein levels with MGMT and IDH1 status. MGMT was methylated in 22.2% and
IDH1 was mutated in 14.8% of these patients. We estimated the difference in average RPS11
expression between patient subgroups. Patients with unmethylated MGMT exhibited higher
RPS11 expression levels (mean difference = 0.52, 95% C.I. 0.05–0.99, p = 0.04), when compared
to patients with methylated MGMT. Patients with wild-type IDH1 exhibited higher RPS11
expression levels (mean difference = 0.64, 95% C.I. 0.09–1.19, p = 0.03) when compared to
patients with mutant IDH1. However, in our study population, MGMTmethylation was not
significantly associated with survival (HR = 1.38, p = 0.62) (Fig 5). IDH1 mutant GBM patients
had a trend towards improved survival (HR = 7.9, p = 0.06) (Fig 5). These findings may be
related to the modest number of total cases and the low percentages of MGMT-methylated and
IDH1-mutant cases. RPS11 expression and age at diagnosis were significantly associated with
survival (Fig 5). Patients diagnosed after the age of 60 exhibiting a 4-fold increase in their death
hazard, (HR = 4.44, p = 0.02) (Fig 5). Multivariate analysis was not meaningful given the rela-
tively small number of cases.
Elevated transcription levels of RPS11 and RPS20 together are strongly
associated with poor survival in a large TCGA dataset of primary
glioblastoma
To confirm the prognostic value of RPS11, we expanded our investigation to gene expression
(mRNA) levels and their correlation with survival of primary GBM patients in publicly
Fig 3. Kaplan-Meier survival curves for newly diagnosed and recurrent GBMs expressed differential levels of selected signatures of TRGC. These
survival curves for RPS11, RPS20, and VEGFA correspond to the Cox Proportional Hazards data in Table 1. Both primary and secondary GBMs were
included in the analyses.
doi:10.1371/journal.pone.0141334.g003
Table 2. Tissuemicroarray protein expression- Cox proportional hazard analysis (primary GBMs only).
Biomarker All GBMs Newly Diagnosed Recurrent
HR (95%CI) [p value] HR (95%CI) [p value] HR (95%CI) [p value]
RPS11 (Expression > 1.3) 3.95(1.52–10.28) [0.005] 11.46 (2.71–48.33) [<0.01] 1.45 (0.37–5.65) [0.65]
RPS20 (Expression > 1.8) 2.58 (1.20–5.58) [0.02] 4.51 (1.19–17.10) [0.03] 2.26 (0.94–5.46) [0.13]
VEGFA (Expression > 1.8) 1.47 (0.55–3.94) [0.44] 2.83 (0.72–11.15) [0.14] 0.76 (0.21–2.72) [0.73]
RPS11 and RPS20 4.09 (1.26–13.26) [0.02] 17.99 (3.01–107) [0.001] NA
Age-adjusted estimates
RPS11 (Expression > 1.3) 3.85 (1.64, 9.01) [<0.01] 6.82 (2.05–22.66) [<0.01] 1.50 (0.37–6.14) [0.63]
RPS20 (Expression > 1.8) 2.06 (0.94–4.56) [0.07] 3.94 (1.28–12.17) [0.049] 0.96 (0.34–2.75) [0.95]
VEGFA (Expression > 1.8) 0.98 (0.42–2.31) [0.97] 1.39 (0.43–4.46) [0.65] 0.46 (0.13–1.70) [0.33]
RPS11 and RPS20 5.84 (1.64–20.8) [<0.01] 19.9 (2.65–251) [0.001] NA
doi:10.1371/journal.pone.0141334.t002
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available TCGA transcription data (n = 578 GBM) (https://tcga-data.nci.nih.gov/tcga/)
(Table 4). Patients with RPS11 mRNA expression higher than average had a tendency towards
a 20% increase in the hazard of death when compared with patients with lower than average
RPS11 expression (95%CI: 0.99–1.43, p = 0.06). In a continuous expression analysis, we
observed a 19% increase in the hazard of death with increased expression of RPS20 gene (95%
CI: 1.04–1.51 p = 0.01). In a binned analysis, patients with higher than average RPS20 expres-
sion had a trend towards a 25% increase in the hazard of death compared to patients with
lower than average RPS20 expression (p = 0.02). Patients with either overexpressed RPS11 or
overexpressed RPS20 had a trend towards a 20% increase in the hazard of death relative to
those with low RPS11 or RPS20 (95% CI: 0.97–1.49, p = 0.09). Strikingly, patients with both
RPS11 and RPS20 overexpression exhibited a 43% increase in the hazard of death (95% CI:
1.11–1.83, p = 0.01) relative to those with low RPS11 and RPS20 expression. In the IDH1 copy-
number variation (CNV)-adjusted analyses, results remain substantially unchanged. On the
Fig 4. Upregulation of protein levels of TRGC signatures in GBM subgroups correlates with patients' poor prognosis. Representative
immunohistochemical staining of RPS11 and RPS20 in clinical GBM subgroups. Upregulation of RPS11 was found to increase the hazard of death (HOD)
11-fold in newly diagnosed primary GBM (a, b) (Table 2) and 7-fold in a secondary GBM (c, d) (S2 Table). Upregulation of RPS20 was found to increase the
HOD 5-fold in newly diagnosed primary GBM (e, f) (Table 2). The survival times of each representative patient are shown.
doi:10.1371/journal.pone.0141334.g004
Table 3. Correlation with poor survival in newly diagnosed and recurrent GBMs (primary and secondary GBMs included).
Biomarker(s) Gene expression Protein expression
Probe Set Analyzer Tissue microarray IHC- GBM
Newly diagnosed Recurrent Newly diagnosed Recurrent
(p value) (p value) HR (P value) HR (P value)
RPS11 <0.001 0.32 9.29 (<0.001) 2.61 (0.13)
RPS20 0.0065 <0.001 1.45 (0.56) 2.36 (0.07)
VEGFA 0.66 <0.001 3.46 (0.03) 1.12 (0.86)
doi:10.1371/journal.pone.0141334.t003
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other hand, in both the IDH1 CNV and MGMTmethylation status-adjusted analyses, similar
results were obtained except the association between RPS11 mRNA expression and patient sur-
vival was not seen (Table 4). However, we should note that considering MGMTmethylation
Fig 5. Correlations of the expression level of RPS11, the status of MGMTmethylation, IDHmutation and age with patient survival. Each indicated
factor was analyzed as an independent prognostic factor. Changes in relative risk were depicted with Kaplan-Meier curves and analyzed using log-rank tests.
doi:10.1371/journal.pone.0141334.g005
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depletes the original TCGA sample to only 290 subjects with available methylation data. We
did not find any association between VEGFA mRNA expression and patient survival (Table 4).
Discussion
In this study, we evaluated whether molecular defense signatures of TRGC could be used to
identify biomarkers predictive of patient survival. We investigated both transcriptional and
protein levels. Our strategy was to screen TRGC gene expression defense signatures using
Probe Set Analyzer as an initial step to select candidate genes with prognostic value. This was
followed by immunohistochemical analysis of GBM TMA and whole GBM tissues for the veri-
fication at the protein level, and finally correlation with a TCGA gene expression dataset. (S2A
Fig). This proof-of-concept investigation of the prognostic value of TRGC markers demon-
strates that TRGC defense signatures can be translated to patient prognosis. The results also
suggest that TRGC are a clinically relevant model of the cell population within a GBM tumor
that confers treatment resistance and facilitates development of tumor recurrence. Although
increased RPS11 protein expression levels in either primary or secondary GBM tumors
were associated with an increased hazard of death (Primary: HR = 3.95, p = 0.005; Secondary:
HR = 6.85, p = 0.05), the prognostic significance was markedly enhanced when analysis was
performed in newly diagnosed GBM (HR = 9.29, p<0.001) or newly diagnosed primary GBM
(HR = 11.46, p<0.001). By contrast, the prognostic significance of RPS20 protein expression
was only detected in primary GBM (HR = 2.58, p<0.02) or newly diagnosed primary GBM
(HR = 4.51, p = 0.03). Concurrent increased expression of RPS11 and RPS20 in patients with
newly diagnosed primary GBM showed an 18-fold increased hazard of death. This observation
was also supported by the TCGA dataset, which showed that newly diagnosed primary GBM
patients with both RPS11 and RPS20 overexpression exhibited a 43% increase in the hazard of
death when compared to 19% and 25% increases for RPS11 and RPS20 individually. These
data therefore support the view that upregulation of both RPS11 and RPS20 expression in
patients with newly diagnosed primary GBMmost robustly predicts a poor prognosis.
While RPS11 protein levels alone is a strong prognostic factor in newly diagnosed GBM or
newly diagnosed primary GBM, elevated transcriptional levels only closely approached signifi-
cance in the TCGA gene expression dataset (HR = 1.19, p = 0.06). This discrepancy may be
due to the relative selectivity of immunohistochemical scoring for tumor cells and the stability
of proteins, while global gene expression measurements are susceptible to perturbation by pre-
analytical variables and by intermixed non-neoplastic neuroglial, vascular, and inflammatory
cells. Moreover, increased RPS11 protein level is associated with known unfavorable prognostic
markers- unmethylated MGMT and wild-type IDH1 status, consistent with the premise that
measurement of RP protein levels is clinically relevant. RPs are a major component of
Table 4. TCGA analysis—correlation with poor survival in newly diagnosed primary GBMs.
Biomarker(s) Gene expression TCGA
Univariate Analysis IDH1 Adjusted Estimates IDH1 and MGMT Adjusted Estimates
HR (95% CI) [P value] HR (95% CI) [P value] HR (95% CI) [P value]
RPS11 1.19 (0.99, 1.44) [0.06] 1.19 (0.99, 1.44) [0.06] 1.01 (0.77, 1.32) [0.96]
RPS20 1.25 (1.03, 1.50) [0.02] 1.24 (1.03, 1.50) [0.02] 1.35 (1.03, 1.77) [0.03]
RPS11 or RPS20 1.19 (0.97, 1.46) [0.09] 1.17 (0.94, 1.46) [0.15] 1.19 (0.87, 1.63) [0.29]
RPS11 and RPS20 1.43 (1.11, 1.83) [0.01] 1.42 (1.11, 1.83) [0.01] 1.31 (0.91, 1.90) [0.14]
VEGFA 1.12 (0.93, 1.35) [0.2] 1.13 (0.93, 1.36) [0.21] 1.10 (0.83, 1.46) [0.50]
doi:10.1371/journal.pone.0141334.t004
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ribosomes that coordinate protein biosynthesis in the cytoplasm of cells. However, accumu-
lated evidence from early studies have demonstrated that RPs have extraribosomal roles
including cell cycle checkpoint, cell survival, malignant transformation, cell apoptosis/death,
DNA repair, transcription, RNA processing, and anti-inflammatory functions [41–44]. Upre-
gulation of transcripts for RPs in various types of human malignancies has been reported [45–
48]. Increased expression of RPs in tumors are correlated with clinical stage and associated
with poor survival [49, 50], suggesting the possibility that excess RP production in tumors may
predict increased stress resistance to standard treatment. The expression of RPS11 protein was
barely detected in normal colon mucosa but was upregulated in immature mucosal epithelium
located in the crypt base and in colorectal carcinoma cells [46]. Importantly, it was shown that
the expression of RPS11 does not significantly change in either human fibroblasts or peripheral
blood mononuclear cells when subjected to a serum or mitogen stimulation, whereas RPS11
mRNAs rapidly decrease in HL60 leukemia cells induced to terminal differentiation by retinoic
acid [51]. Moreover, RPS11 was shown to be specifically downregulated in apoptotic breast car-
cinoma cells [52]. These observations support the notion that upregulation of RPS11 may pro-
mote cells to remain in a dedifferentiated state that in turn renders them relatively resistant to
environmental stress.
Recently, multiple lines of evidence have shown that a number of RPs are mouse double
minute 2 homolog (MDM2)-binding partners, and it is suggested that, under nucleolar stress
conditions, free RPs are released to the nucleoplasm where they interact with MDM2, leading
to blockage of its E3 ligase function and resulting in the stabilization and activation of p53 [52–
55]. A recent study has shown that nutrient deprivation inhibited ribosomal RNA biosynthesis
and increased RP-MDM2 interaction, an acute stress response, leading to p53 activation and
induction of p53-mediated transactivation of malonyl-CoA decarboxylase, thereby stimulating
fatty acid oxidation, a catabolic pathway in response to nutrient depletion [56]. In concordance
with this finding, we also found an association of treatment resistance with energy stress in
TRGC that favor lipid catabolism as their major energy source [25]. Thus, upregulation of
RPS11 in quiescent TRGC or in tumors may be associated with maintenance of a stem-like,
stress-resistant phenotype. This may also explain that the association of upregulation of RPS11
with poor prognosis is more pronounced in patients with newly diagnosed primary GBM, a
GBM subtype that more often lacks p53 mutations than secondary GBM [57, 58]. Moreover,
prognostic significance of RPS11 was shown in newly diagnosed GBM but not in recurrent
tumors, suggesting that RPS11 upregulation is of benefit to GBM tumor cells at initial treat-
ment when radiochemotherapy is given to essentially all newly diagnosed GBM patients. Post-
radiochemotherapy and after further evolution, it may be that recurrent GBM have acquired
genetic or epigenetic changes that are biologically more important for outcome than RPS11.
Like RPS11, RPS20 is one of the RPs that can also bind to MDM2 and activate p53 [59] and it
was reported that overexpression of RPS20 is associated with an adverse outcome in medullo-
blastoma [60]. Analysis with STRING Interaction Network (http://string-db.org/), a tool that
shows known and predicted protein-protein interactions, indicates that RPS20 directly binds
to RPS11 (S2B Fig). Besides MDM2, two critical proteins that are associated with stress resis-
tance—superoxide dismutase (SOD1) and ubiquitin C (UBC)-, are also linked with the
RPS11-RPS20 protein network (S2B Fig). SOD1 is a vital detoxifying enzyme and a major anti-
oxidant system, and is considered an anti-aging factor [61, 62]. Likewise, UBC is typically
referred to as a stress-inducible gene that can adequately increase expression levels when cells
are challenged with different types of stress; presumably to correct protein misfolding or to
degrade damaged proteins allowing them to survive under toxic stress conditions [63–65].
These findings suggest that upregulation of RPS11 and RPS20 contributes to an anti-stress phe-
notype by enhancing genomic and cellular stability.
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In this study, VEGFA, a factor targeted by bevacizumab therapy, is associated with poor
prognosis only in newly diagnosed GBM or secondary GBM but not in primary GBM alone.
Similarly, VEGFA analysis of the TCGA dataset where primary GBM were evaluated did not
show an association with prognosis. Probe Set Analyzer did not have data for secondary GBM
to compare against our protein data. Future study of this GBM subset is desirable. In contrast,
RPS11 and/or RPS20 are robust prognostic factors. Targeted therapy that aims to reduce these
RPs may potentially reverse the stress-resistant phenotype and sensitize tumors to standard
radiochemotherapy. Given their ubiquity, targeted therapy against RPs without adversely
affecting normal cells is likely to prove challenging. Identification of unique transcriptional
inducers that promote the overexpression of RPS11 and RPS20 in GBM could facilitate eluci-
dation of the underlying biology and identification of additional prognostic factors or treat-
ment targets.
This study strongly supports the concept of TRGC as a useful cellular model and a resource
for identifying novel GBM prognostic biomarkers. We have found that overexpression of
RPS11 and RPS20 can predict decreased survival in patients with newly diagnosed primary
GBM at either the transcriptional or protein levels. RPS11 and RPS20 together have greater
prognostic value than VEGFA, a major target of current therapy, suggesting that these RPs are
worthwhile targets of novel therapeutic strategies.
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